Bico Group AB logo

Bico Group AB (49Z)

Market Closed
12 Dec, 20:00
XFRA XFRA
1. 73
+0.01
+0.46%
247.8M Market Cap
- P/E Ratio
0% Div Yield
22 Volume
0 Eps
1.72
Previous Close
Day Range
1.71 1.73
Year Range
1.64 4.1
Want to track 49Z and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 66 days

Summary

49Z closed Friday higher at €1.73, an increase of 0.46% from Thursday's close, completing a monthly decrease of -7.13% or €0.13. Over the past 12 months, 49Z stock lost -38.49%.
49Z is not paying dividends to its shareholders.
The last earnings report, released on Nov 04, 2025, exceeded the consensus estimates by 0.98%. On average, the company has surpassed earnings expectations by 0.59%, based on the last three reports. The next scheduled earnings report is due on Feb 18, 2026.
The stock of the company had never split.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on XFRA (EUR).

49Z Chart

Similar

0MD
Squirrel Media S.A.
2.3
-2.95%
W06
Anders J Ahlstrom Holding AB
5.61
-3.61%
0FO
Focusrite Plc
2.24
-3.45%
3S8
North Media A/S
5.68
-1.73%
6H1
Reworld Media S.A.
1.48
-2.12%

Bico Group AB (49Z) FAQ

What is the stock price today?

The current price is €1.73.

On which exchange is it traded?

Bico Group AB is listed on XFRA.

What is its stock symbol?

The ticker symbol is 49Z.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 247.8M.

When is the next earnings date?

The next earnings report will release on Feb 18, 2026.

Has Bico Group AB ever had a stock split?

No, there has never been a stock split.

Bico Group AB Profile

Media Industry
Communication Services Sector
Ms. Maria Forss CEO
XFRA Exchange
SE0013647385 ISIN
Sweden Country
711 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Bico Group AB stands at the forefront of the biotechnology sector, championing bio-convergence technologies that merge engineering with biological sciences. With a focus on enhancing human health and well-being, the company has staked its reputation on being an innovator within the realms of bioprinting, tissue engineering, and regenerative medicine. By creating groundbreaking technologies, Bico Group AB has positioned itself as an indispensable partner to pharmaceutical firms, healthcare providers, and academic institutions. Its role in furthering medical science has not only spurred advancements in drug development and personalized medicine but has also attracted significant financial investments into the biotech industry, thereby fueling the ongoing evolution of healthcare solutions and products.

Products and Services

  • Bioprinting Technologies

    Bico Group AB is renowned for its cutting-edge bioprinting technologies, which are pivotal in the creation of three-dimensional tissue models. These technologies play a critical role in research and development within pharmaceutical companies, enabling the testing of new drugs on biologically accurate tissue samples. This accelerates the drug development process significantly, reducing the reliance on animal testing, and paving the way for more ethical and efficient research methodologies.

  • Tissue Engineering and Regenerative Medicine Solutions

    The company's advancements in tissue engineering and regenerative medicine are at the cutting edge of healing and restoration technologies. By fostering the development of tissues and organs in the lab, Bico Group AB's contributions are critical for transplant medicine and for treating diseases that were previously thought to be incurable. These solutions have the potential to revolutionize the medical field by providing life-saving options for patients with organ failures or complex tissue damage.

  • Development Tools for Personalized Medicine

    Bico Group AB produces sophisticated tools and technologies that facilitate the growth of personalized medicine. By enabling the customization of healthcare, with treatments and preventions tailored specifically to individual patients, the company empowers medical providers to achieve better outcomes. Its technologies support the analysis of genetic information, which is key to identifying the most effective treatments for each patient, showcasing the transformative potential of personalized medicine in contemporary healthcare.

Contact Information

Address: LAngfilsgatan 9
Phone: 46 7 35 46 57 77